ngsmsp | 1046
NGS melanoma (spitzoid)
Keywords
ALK, BRAF, CDKN2A, HRAS, MET, Next Generation Sequencing, NRAS, NTRK, Oncomine, PTEN, RET, ROS, TERT
| Material |
|
|
| Note |
Hotspot variants: BRAF, CDKN2A, HRAS, NRAS, TERT. Full gene sequencing: PTEN. Copy number variations: CDKN2A, PTEN. Fusions: ALK, BRAF, ROS1, RET, MET, NTRK1, NTRK2, NTRK3. | There is a possibility of excess information occurring with this analysis. This will be communicated, unless it is noted otherwise when placing the order. Since, in rare cases, findings may also indicate hereditary changes, the Federal Act on Human Genetic Testing (HGTA) requires that patients be appropriately informed (see www.viollier.ch/consent_ssmg). The consent form is intended for internal documentation within the practice and does not need to be submitted to Viollier. Billing: in accordance with TARDOC. |
|
| Duration | 6 days | |
| Frequency | 2 x per week | |
| Method | Next Generation Sequencing | |
| Price | CHF 0.00 | |
| Tariff | 0.00 TP |
Team of consultants
|
Dr. med.
Katharina Marston
FMH Pathology, molecular pathology
|
FMH Pathology, molecular pathology | T |
|
|
Dr. rer. nat.
Henriette Kurth
FAMH Specialist in laboratory medicine, medical genetics
|
FAMH Specialist in laboratory medicine, medical genetics | T |
|
|
Dr. med.
Jean-François Egger
FMH pathology
|
FMH pathology | T |
|
|
PD Dr. med.
Andreas Zettl
FMH pathology, molecular pathology
|
FMH pathology, molecular pathology | T |
|
|
Dr. med.
Santiago Giménez de Mestral
FMH pathology, cytopathology
|
FMH pathology, cytopathology | T |
|